Biotech · Private company · Houston, TX, US
7 Hills Pharma, LLC
Track this companyFree. Adds 7 Hills Pharma, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- AlintegimodPhase 2 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- IpilimumabPhase 2 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- 7HP349 Food EffectPhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- 7HP349 Multiple Ascending DosePhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- 7HP349 Single Ascending DosePhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyPHASE1_PHASE2 · RECRUITING · started Aug 23, 2024ClinicalTrials.gov NCT06362369 · fetched Nov 12, 2026
- A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male SubjectsPHASE1 · COMPLETED · started Oct 28, 2020ClinicalTrials.gov NCT04508179 · fetched Nov 12, 2026
NIH awards3
- Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infectionFiscal year 2024 · $997.9KNIH RePORTER 5R44AI172437-03 · fetched Nov 12, 2026
- 7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccinationFiscal year 2024 · $953.5KNIH RePORTER 5R44AI176894-02 · fetched Nov 12, 2026
- 7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid TumorsFiscal year 2024 · $999.2KNIH RePORTER 5R44CA285207-02 · fetched Nov 12, 2026